Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.

Item
http://www.wikidata.org/entity/Q33602351
Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.Characteristic clinical features of Aspergillus appendicitis: Case report and literature review.Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts.A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile NeutropeniaClinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myeIncidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
P2860

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.

Item
http://www.wikidata.org/entity/Q33602351
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@ast
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
type
label
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@ast
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
prefLabel
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@ast
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P577
P5875
P698
P921
P932